

			Revenue estimates million DKR				
	Royalty	Peaksale	2021	2022	2023	2024	2025
Daratumumab (CD38) MM (Janssen Biotech)	17.5%	10B\$USD	6665	7665	8665	9665	10500
AL Amyloidosis (Dara)							
Non MM blod cancers : phase 2 (Dara)							
Ofatumumab (CD20) MS (Novartis Pharma)	10%	2.5B\$USD	217	434	781.2	1171.8	1550
Teprotumumab (IGF-1R) Thyroid eye disease (Horizon)	7%	4B\$USD	550	850	1150	1450	1736
Amivantamab (Janssen)	10%	1B\$USD	75	155	250	400	620
Tisotumab Vedotin (Cervical) Seagen Inc.	50/50	500M\$USD	90	180	375	750	1550
Ovarian Cancer	50/50						
Solid tumors	50/50						
Epcoritamab - 1st sale Q4 - 2022 AbbVie	50/50	5B\$USD	0	250	5000	10000	15500
HexaBody-CD38							
DuoBody, BNT311-GEN1046 - Phase 1/2 data H2-2021 (BioNTech) - solid tumors	50/50						
Total			7597	9534	16221.2	23436.8	31456

Revision 9 - August 04-2021

USD / DKK

6.2